Drugs / Nicotine gum
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02356913 | Apr → May 2014 | — | Fertin Pharma A/S | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03722966 | Jan 2020 → Feb 2022 | — | University of Oklahoma | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05413122 | Nov 2023 → Aug 2027 expected | HIV infectious disease | Johns Hopkins University | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT01621022 Comparator | Jan 2001 → Oct 2002 | nicotine dependence | University of Wisconsin, Madison | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nicotine gum | “Nicotine Gum (4mg)” NCT03722966 ↗ |
| Modality | Other / unclassified | “oral nicotine replacement therapy (4mg gum or 4mg lozenge, depending on preference; to be used every 1-2 hours as urges occur)” NCT03722966 ↗ |
| Route | Oral | “4 mg nicotine gum; single dose; chewed 30 minutes” NCT02356913 ↗ |